# 為了讓複雜的生物製劑藥物更負擔得起，FDA提議放寬生物相似藥的測試規定。

*biotech · news · 2026-03-10 · Devdiscourse*

## Key points

- FDA提議放寬生物相似藥的測試規定，以降低複雜生物製劑藥物的成本。
- 生物製劑藥物佔藥物支出超過一半，但僅佔處方量的5%。
- 西班牙研究人員利用魚鱗製成人工角膜，作為比捐贈移植更便宜的替代方案。
- 中國在聯合國會議上反駁美國關於芬太尼前驅物銷售管控不足的指控。

In an effort to make complex biologic medicines more affordable, the FDA proposed easing rules for biosimilar drug testing. This initiative targets high-cost treatments for cancer and autoimmune diseases, currently dominating over half of the market's drug spending, despite comprising just 5% of prescriptions. At a United Nations meeting, the United States and China engaged in a heated exchange, with accusations from Washington that Beijing is lax on controlling fentanyl precursor sales. China refuted the claims, intensifying tensions ahead of a planned diplomatic meeting at the month's end. Spanish researchers have pioneered an innovative artificial cornea using fish scales, offering a lower-cost substitute for traditional donor transplants used to treat severe eye diseases. The scarcity of donor corneas makes this breakthrough particularly significant in addressing the pressing demand.

**Countries:** United States, China

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3833425-fdas-bold-move-boosts-biosimilars-us-china-tensions-over-fentanyl-artificial-cornea-innovation)

---

Canonical: https://newsio.io/zh-TW/n/989ef300-75a9-48b5-b629-7c67094ab492/fda
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works